<?xml version="1.0" ?>
<document id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4">
  <chunk id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c0" text="Remission of Invasive, Cancer Stem-Like Glioblastoma Xenografts Using Lentiviral Vector-Mediated Suicide Gene Therapy">
    <entity charOffset="23-29" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c0.e0" ontology_id="DOID_162" text="Cancer" type="disease"/>
  </chunk>
  <chunk id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c1" text="Background: Glioblastoma is the most frequent and most malignant primary brain tumor with a poor prognosis. The translation of therapeutic strategies for glioblastoma from the experimental phase into the clinic has been limited by insufficient animal models, which lack important features of human tumors. Lentiviral gene therapy is an attractive therapeutic option for human glioblastoma, which we validated in a clinically relevant animal model.">
    <entity charOffset="55-84" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c1.e0" ontology_id="DOID_1319" text="malignant primary brain tumor" type="disease"/>
  </chunk>
  <chunk id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2" text="We used a rodent xenograft model that recapitulates the invasive and angiogenic features of human glioblastoma to analyze the transduction pattern and therapeutic efficacy of lentiviral pseudotyped vectors. Both, lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) and vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vectors very efficiently transduced human glioblastoma cells in vitro and in vivo. In contrast, pseudotyped gammaretroviral vectors, similar to those evaluated for clinical therapy of glioblastoma, showed inefficient gene transfer in vitro and in vivo. Both pseudotyped lentiviral vectors transduced cancer stem-like cells characterized by their CD133-, nestin-and SOX2-expression, the ability to form spheroids in neural stem cell medium and to express astrocytic and neuronal differentiation markers under serum conditions. In a therapeutic approach using the suicide gene herpes simplex virus thymidine kinase (HSV-1-tk) fused to eGFP, both lentiviral vectors mediated a complete remission of solid tumors as seen on MRI resulting in a highly significant survival benefit (p,0.001) compared to control groups. In all recurrent tumors, surviving eGFP-positive tumor cells were found, advocating prodrug application for several cycles to even enhance and prolong the therapeutic effect.">
    <entity charOffset="213-241" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e0" ontology_id="DOID_12155" text="lymphocytic choriomeningitis" type="disease"/>
    <entity charOffset="248-260" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e1" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="285-295" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e2" ontology_id="DOID_9637" text="stomatitis" type="disease"/>
    <entity charOffset="302-314" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e3" ontology_id="CHEBI_17089" text="glycoprotein" type="chemical"/>
    <entity charOffset="646-652" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e4" ontology_id="DOID_162" text="cancer" type="disease"/>
    <entity charOffset="921-935" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e5" ontology_id="DOID_8566" text="herpes simplex" type="disease"/>
    <entity charOffset="942-951" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e6" ontology_id="CHEBI_17748" text="thymidine" type="chemical"/>
    <entity charOffset="1243-1250" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e7" ontology_id="CHEBI_50266" text="prodrug" type="chemical"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e0" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e1" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p0" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e0" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e3" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p1" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e0" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e6" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p2" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e0" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e7" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p3" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e1" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e2" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p4" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e1" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e4" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p5" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e1" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e5" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p6" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e2" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e3" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p7" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e2" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e6" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p8" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e2" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e7" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p9" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e3" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e4" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p10" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e3" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e5" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p11" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e4" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e6" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p12" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e4" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e7" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p13" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e5" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e6" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p14" relation="true"/>
    <pair e1="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e5" e2="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.e7" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c2.p15" relation="true"/>
  </chunk>
  <chunk id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c3" text="Conclusions/Significance: In conclusion, lentiviral pseudotyped vectors are promising candidates for gene therapy of glioma in patients. The inefficient gene delivery by gammaretroviral vectors is in line with the results obtained in clinical therapy for GBM and thus confirms the high reproducibility of the invasive glioma animal model for translational research.">
    <entity charOffset="255-258" id="63205fe99a388f19fde06f422c9ce6c1ddfc52f4.c3.e0" ontology_id="DOID_3068" text="GBM" type="disease"/>
  </chunk>
</document>
